Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration

Indian Journal of Ophthalmology

Volumn 61, Issue 9, 2013, Pages 490-496

  Jain, Sachin ^a,b   Kishore, Kamal ^a,b   Sharma, Yog Raj ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Illinois Retina Institute   (United States)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti VEGF injections; bevacizumab; neovascular age related macular degeneration; ranibizumab; submacular hemorrhage

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL HEMORRHAGE; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84886539629     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.119432     Document Type: Article

References (34)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85
2. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hem-orrhage. Am J Ophthalmol 1996;122:486-93
3. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33-7
4. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762-73
5. Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991;109:723-9
6. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 2004;111:1993-2006
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
8. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
9. Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900-6
10. Singh P, Singh R, Kishore KS, Vig VK, Singh R, Singh B. Intravitreal tissue plasminogen activator in submacular haemorrhage. Indian J Ophthalmol 1999;47:254-5
11. Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hem-orrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326-32
12. Mahesh G, Giridhar A, Saikumar SJ, Elias A. Intravitreal gas for submacular haemorrhage. Indian J Ophthalmol 2003;51:349-50
13. Chawla S, Misra V, Khemcandani M. Pneumatic displacement and intravitreal bevacizumab: A new approach for management of submacular hemorrhage in choroidal neovascular membrane. Indian J Ophthalmol 2009;57:155-7
14. Agarwal M, Chaudhary SP, Narula R, Rajpal S. Pneumatic displacement and intravitreal bevacizumab for management of submacular hemorrhage in choroidal neovascular membrane. Indian J Ophthalmol 2010;58:170-1
15. Guthoff R, Guthoff T, Meigen T, Goebel W. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina 2011;31:36-40
16. Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: A comparison of submacular hemorrhage/membrane removal and sub-macular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc 2005;103:98-107
17. Wade EC, Flynn HW Jr, Olsen KR, Blumenkranz MS, Nicholson DH. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol 1990;108:973-8
18. Haupert CL, McCuen BW 2nd, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for dis-placement of thick submacular hemorrhage in age-related macular degeneration. Am J Opthamol 2001;131:208-15
19. Shah SP, Hubschman JP, Gonzales CR, Schwartz SD. Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2009;40:308-15
20. Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol 2012;96:708-13
21. Steel DH, Sandhu SS. Submacular haemorrhages associated with neovascular age-related macular degeneration. Br J Ophthalmol 2011;95:1051-7
22. Charles S, Calzada J, Wood B. Vitreous Microsurgery. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 168-9
23. Gehrs KM, Heriot WJ, de Juan E Jr. Transmission electron microscopic study of a subretinal choroidal neovascular membrane due to age-related macular degeneration. Arch Ophthalmol 1992;110:833-7
24. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, et al. Intravitreal bevaci-zumab therapy for neovascular age-related macular degeneration with large submacular hemor-rhage. Am J Ophthalmol 2007;144:886-92
25. Sacu S, Stifter E, Vécsei-Marlovits PV, Michels S, Schütze C, Prünte C, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond) 2009;23:1404-10
26. McKibbin M, Papastefanou V, Matthews B, Cook H, Downey L. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye (Lond) 2010;24:994-8
27. Hesgaard HB, Torkashvand M, la Cour M. Failure to detect an effect of pneumatic displacement in the management of submacular haemorrhage secondary to age-related macular Degeneration: A retrospective case series. Acta Ophthalmol 2012;90:e498-500
28. Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 2010;30:1171-6
29. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
30. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevaci-zumab for treatment of neovascular age-related macular degeneration: Two-year results. Oph-thalmology 2012;119:1388-98
31. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and eco-nomic impact. Ophthalmology 2010;117:2134-40
32. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci 2006;47:1236-40
33. Levine JP, Marcus I, Sorenson JA, Spaide RF, Cooney MJ, Freund KB. Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy. Retina 2009;29:1074-9
34. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection fre-quency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macu-lar degeneration. Ophthalmology 2009;116:1740-7